McHale Duncan 4
4 · Evelo Biosciences, Inc. · Filed Jan 21, 2022
Insider Transaction Report
Form 4
McHale Duncan
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-01-19+100,000→ 100,000 totalExercise: $5.05Exp: 2032-01-19→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates.